Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) EBITDA Margin (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed EBITDA Margin for 7 consecutive years, with 3019.23% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 201614.0% to 3019.23% in Q4 2025 year-over-year; TTM through Dec 2025 was 785.66%, a 30812.0% decrease, with the full-year FY2025 number at 785.66%, down 30812.0% from a year prior.
  • EBITDA Margin was 3019.23% for Q4 2025 at Kymera Therapeutics, down from 2928.84% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 26.04% in Q4 2023 to a low of 3019.23% in Q4 2025.
  • A 5-year average of 695.07% and a median of 382.06% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: skyrocketed 29812bps in 2021, then tumbled -201614bps in 2025.
  • Kymera Therapeutics' EBITDA Margin stood at 225.3% in 2021, then rose by 7bps to 210.06% in 2022, then skyrocketed by 88bps to 26.04% in 2023, then crashed by -3752bps to 1003.08% in 2024, then tumbled by -201bps to 3019.23% in 2025.
  • Per Business Quant, the three most recent readings for KYMR's EBITDA Margin are 3019.23% (Q4 2025), 2928.84% (Q3 2025), and 664.67% (Q2 2025).